a-ee85aqa.blogspot.com
After reaching a 52-week high of $7.53 per sharr on April 16, the company's sharesw are now trading at around $4.19 a shar on the Nasdaq. The Dubli n company has $86.6 million in cash and no debt at the end of its secon d quarterthis year. Its leading a drug that knockss out the proteins that help cancere cells growand spread, could move into a Phase 1b trialk later this year, Manusl said. That's a significant step closer to FDA Four other drugs developefd withthe company's fast computer modeling system are in line for latee testing. Dacogen, a treatment for leukemia-linkex bone marrow disease the company licensesto , could earn the company $21 million in royalty said Manuso.
American Technology Research, a Connecticut analysft firm, initiated coverage of SuperGen 5 witha "buy" rating, saying thosew payments support a higher valuationn for the company's shares, which it thinksz could reach $8 per share. In the last the stock has rangedbetween $3.921 to $7.53. Manuso made a presentation at Healthcars Conference inBoston Sept. 4. He'lkl present at Bear Stearns Healthcarre Conference in New York Cityon Sept. 11, ThinkEquityy Partners' Fifth Annual Growth Conference in San Francisco latethis month, and at A.G. Edwards Second Annual Emerging Growth Conference in New YorkCity 18.
Some of the other East Bay biotechy executives on the conference trackthis month: CFO David Smith will present at CEO Robert Johnson, CEO Joerg and CEO Mark McDade will present at Bear Representatives of , , and PDL's McDade will present at the Thin Equity. Representatives of and will presentfat A.G. Edwards.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment